23.25 USD
-0.03 (-0.13%)
Overall CPRX gets a fundamental rating of 8 out of 10. We evaluated CPRX against 533 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
CPRX had a positive operating cash flow in the past year.
CPRX had positive earnings in each of the past 5 years.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 20.69%, CPRX belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
With an excellent Return On Equity value of 23.65%, CPRX belongs to the best of the industry, outperforming 96.62% of the companies in the same industry.
The Return On Invested Capital of CPRX (21.23%) is better than 97.75% of its industry peers.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is in line with the industry average of 18.83%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.23%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
CPRX's Profit Margin of 37.64% is amongst the best of the industry. CPRX outperforms 96.81% of its industry peers.
CPRX's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 44.78%, CPRX belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
CPRX's Operating Margin has improved in the last couple of years.
The Gross Margin of CPRX (85.68%) is better than 87.80% of its industry peers.
CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CPRX has more shares outstanding
Compared to 5 years ago, CPRX has more shares outstanding
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 15.85 indicates that CPRX is not in any danger for bankruptcy at the moment.
CPRX has a Altman-Z score of 15.85. This is amongst the best in the industry. CPRX outperforms 88.37% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.85 |
ROIC/WACC2.44
WACC8.7%
2.3 Liquidity
CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a better Current ratio (6.62) than 68.67% of its industry peers.
A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
CPRX has a Quick ratio of 6.40. This is in the better half of the industry: CPRX outperforms 67.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.80% on average per year.
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CPRX is valuated correctly with a Price/Earnings ratio of 13.52.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 95.87% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (25.47), we can say CPRX is valued slightly cheaper.
A Price/Forward Earnings ratio of 13.50 indicates a correct valuation of CPRX.
CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.62% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.42. CPRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 13.5 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 97.94% of the companies are valued more expensively.
CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.18 | ||
| EV/EBITDA | 7.32 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1
PEG (5Y)0.39
EPS Next 2Y14.64%
EPS Next 3Y10.93%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPRX (11/24/2025, 1:25:43 PM)
23.25
-0.03 (-0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change1.43%
Ins Owners5.59%
Ins Owner Change1.61%
Market Cap2.86B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (51.35%)
Short Float %6.93%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)18.46%
EPS beat(12)11
Avg EPS beat(12)14.56%
EPS beat(16)13
Avg EPS beat(16)9.74%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)1.47%
PT rev (3m)1.47%
EPS NQ rev (1m)6.62%
EPS NQ rev (3m)9.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)3.08%
Revenue NQ rev (3m)3.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 13.5 | ||
| P/S | 4.94 | ||
| P/FCF | 12.18 | ||
| P/OCF | 12.17 | ||
| P/B | 3.11 | ||
| P/tB | 3.61 | ||
| EV/EBITDA | 7.32 |
EPS(TTM)1.72
EY7.4%
EPS(NY)1.72
Fwd EY7.41%
FCF(TTM)1.91
FCFY8.21%
OCF(TTM)1.91
OCFY8.22%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)1
PEG (5Y)0.39
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.85 |
F-Score6
WACC8.7%
ROIC/WACC2.44
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.